These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 15305414)

  • 1. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.
    Lai R; Dang CT; Malkin MG; Abrey LE
    Cancer; 2004 Aug; 101(4):810-6. PubMed ID: 15305414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
    Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
    Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.
    Montagna E; Cancello G; D'Agostino D; Lauria R; Forestieri V; Esposito A; Silvestro L; Accurso A; De Placido S; De Laurentiis M
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):275-80. PubMed ID: 18379783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system metastases in breast cancer patients administered trastuzumab.
    Duchnowska R; Szczylik C
    Cancer Treat Rev; 2005 Jun; 31(4):312-8. PubMed ID: 15979804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.
    Gori S; Rimondini S; De Angelis V; Colozza M; Bisagni G; Moretti G; Sidoni A; Basurto C; Aristei C; Anastasi P; Crinò L
    Oncologist; 2007 Jul; 12(7):766-73. PubMed ID: 17673608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.
    Musolino A; Ciccolallo L; Panebianco M; Fontana E; Zanoni D; Bozzetti C; Michiara M; Silini EM; Ardizzoni A
    Cancer; 2011 May; 117(9):1837-46. PubMed ID: 21509760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
    Leyland-Jones B
    J Clin Oncol; 2009 Nov; 27(31):5278-86. PubMed ID: 19770385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive central nervous system metastases in responder patients for outside central nervous system metastases on trastuzumab-based therapy--report of two cases of refractory breast cancer.
    Okita R; Saeki T; Takashima S; Aogi K; Ohsumi S
    Hiroshima J Med Sci; 2005 Mar; 54(1):35-8. PubMed ID: 15847063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.
    Montemurro F; Aglietta M
    Cancer; 2005 Mar; 103(6):1314-5; author reply 1315. PubMed ID: 15674855
    [No Abstract]   [Full Text] [Related]  

  • 10. [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].
    Svoboda M; Grell P; Simícková M; Fabian P; Petráková K; Palácová M; Macková D; Trojanec R; Hajdúch M; Pavlík T; Nenutil R; Vyzula R
    Klin Onkol; 2008; 21(6):348-58. PubMed ID: 19382598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
    Stemmler HJ; Schmitt M; Willems A; Bernhard H; Harbeck N; Heinemann V
    Anticancer Drugs; 2007 Jan; 18(1):23-8. PubMed ID: 17159499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab.
    Yau T; Swanton C; Chua S; Sue A; Walsh G; Rostom A; Johnston SR; O'Brien ME; Smith IE
    Acta Oncol; 2006; 45(2):196-201. PubMed ID: 16546866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment.
    Gonzalez-Angulo AM; Cristofanilli M; Strom EA; Buzdar AU; Kau SW; Broglio KR; Smith TL; Hortobagyi GN
    Cancer; 2004 Oct; 101(8):1760-6. PubMed ID: 15386311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended survival in women with brain metastases from HER2 overexpressing breast cancer.
    Church DN; Modgil R; Guglani S; Bahl A; Hopkins K; Braybrooke JP; Blair P; Price CG
    Am J Clin Oncol; 2008 Jun; 31(3):250-4. PubMed ID: 18525303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
    Brufsky AM; Mayer M; Rugo HS; Kaufman PA; Tan-Chiu E; Tripathy D; Tudor IC; Wang LI; Brammer MG; Shing M; Yood MU; Yardley DA
    Clin Cancer Res; 2011 Jul; 17(14):4834-43. PubMed ID: 21768129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
    Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
    Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
    Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
    Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
    Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.